BNP Paribas Financial Markets Acquires Shares of 9,838 Kymera Therapeutics, Inc. (NASDAQ:KYMR)

BNP Paribas Financial Markets bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,838 shares of the company’s stock, valued at approximately $396,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KYMR. Blue Trust Inc. raised its holdings in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after buying an additional 270 shares in the last quarter. KBC Group NV grew its position in Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in Kymera Therapeutics by 95.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company’s stock worth $194,000 after acquiring an additional 2,350 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock worth $198,000 after acquiring an additional 406 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Kymera Therapeutics in the fourth quarter worth about $251,000.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $29.49 on Monday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The company has a 50 day simple moving average of $28.96 and a two-hundred day simple moving average of $36.29. The company has a market capitalization of $1.92 billion, a PE ratio of -12.60 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. During the same period in the prior year, the firm posted ($0.69) EPS. The company’s quarterly revenue was up 114.6% on a year-over-year basis. Research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. The trade was a 3.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,659 shares of company stock valued at $324,567. 16.01% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. HC Wainwright lifted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. UBS Group decreased their target price on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Stifel Nicolaus began coverage on shares of Kymera Therapeutics in a report on Tuesday, May 20th. They set a “buy” rating and a $55.00 price target for the company. Citigroup began coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target for the company. Finally, Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.25.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.